news releases

19 September 2017

OncoImmune, Inc. Awarded $2 Million SBIR Grant from the National Cancer Institute

OncoImmune, Inc. was awarded a $2,000,000 SBIR grant from the National Cancer Institute to support the phase IIA clinical trial testing  safety and efficacy of CD24Fc in leukemia patients undergoing hematopoietic stem cell transplantation. This…
Read more...
12 January 2017

OncoImmune Announces Series A Financing

OncoImmune, Inc. today announced that is has closed on a $15.0 million Series A round of fundraising led by 3E Bioventures Capital (“3E”).
Read more...
16 September 2016

OncoImmune Doses First Patient in Phase II Clinical Trials for CD24Fc

OncoImmune, Inc. today announced dosing of the first patient at the University of Michigan Medical Center for phase II clinical trial testing safety and efficacy of CD24Fc in leukemia patients undergoing hematopoietic stem cells.  The…
Read more...
26 February 2016

FDA Clears the CD24Fc Application for Use in the Prophylactic Treatment of Acute GVHD

The U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for CD24Fc for use in the prophylactic treatment of acute GVHD. OncoImmune anticipates initiation of its Phase 2 clinical…
Read more...
08 October 2015

OncoImmune Receives Positive Opinion on CD24Fc from the EMA Committee for Orphan Medicinal Products

OncoImmune, Inc. today received a positive opinion from the EMA Committee for Orphan Medicinal Products (COMP) on the application for orphan drug designation of humanized fusion protein consisting of extracellular domain of CD24 linked to…
Read more...
09 June 2015

FDA Grants Orphan-drug Designation for CD24Fc

OncoImmune, Inc. today was granted orphan-drug designation by the FDA for humanized fusion protein consisting of extracellular domain of CD24 linked to IgG1 Fc domain (CD24Fc) for the prevention of graft-versus-host disease.
Read more...

About Us

Based in Rockville, Maryland, OncoImmune is a
privately-held, clinical-stage biopharmaceutical
company that is actively engaged in the discovery
and development of biopharmaceuticals for the
treatment of cancer and autoimmune disease.

Email: This email address is being protected from spambots. You need JavaScript enabled to view it.